Anticoagulantes utilizados en adultos mayores con fibrilación auricular y enfermedad renal crónica. Eficacia y seguridad

Abstract

Background: Atrial fibrillation (AF) and chronic kidney disease (CKD) are emerging diseases affecting millions worldwide and causing significant morbidity and healthcare costs. In patients with coexisting AF and CKD, the incidence of stroke and bleeding increases as renal function declines. Objective: To describe the anticoagulants used in older adults with atrial fibrillation and CKD, their efficacy, and safety. Methodology: The methodological design of this research project will be a narrative literature review. Results: The weighted mean rate of anticoagulant use overall was 57±11%. Older adults with AF and CKD receive direct oral anticoagulants (DOACs) and coumarin anticoagulants (CAs) such as warfarin and acenocoumarol. In addition, direct-acting oral anticoagulants (DOACs) are more effective and safer than vitamin K antagonists (VKAs) in older adults with AF and CKD. Conclusion: Overall, the results indicate that oral anticoagulants effectively prevent thromboembolic events in older adults with atrial fibrillation and CKD, providing a favorable safety profile.